NRG Therapeutics Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, and Domainex Ltd., today announce a collaboration focused on developing novel small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neurone disease (MND) and other debilitating chronic neurodegenerative disorders. Domainex, a leading integrated medicines research services partner, will provide fully integrated lead optimization […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-06-30 08:00:182026-09-10 14:03:29NRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project
£2.68 million Biomedical Catalyst (BMC) early-stage award funded in part by Innovate UK to support development of disease-modifying medicines for debilitating chronic neurodegenerative disorders NRG has a pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson’s disease (PD) and motor neurone disease (MND) NRG […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-05-30 08:00:132026-09-10 14:04:49NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson’s and Motor Neurone Disease
NRG’s second therapeutic programme to explore brain penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) as treatment for MND (ALS) Innovate UK EDGE grant enabled support from the Medicines Discovery Catapult Scientific and commercial insights gained will support MND clinical study design and Series A financing NRG Therapeutics Ltd (“NRG” or “company”), […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-03-01 08:00:112026-07-31 12:36:03NRG Therapeutics Completes MND Therapeutic Analysis Project with Medicines Discovery Catapult Supported by an Innovate UK EDGE Grant
NRG’s second therapeutic programme to explore brain penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) as treatment for MND (ALS) Research collaboration agreement with Australia’s WEHI to work with Associate Professor Seth Masters’ group, on back of groundbreaking research 1 NRG is industrial partner in recent AUD$1 million FightMND Grant to WEHI […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2021-12-16 08:00:142026-07-31 12:37:52NRG Therapeutics Launches MND Drug Discovery Programme and Announces new Collaboration in Australia
NRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project
NRG Therapeutics Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, and Domainex Ltd., today announce a collaboration focused on developing novel small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neurone disease (MND) and other debilitating chronic neurodegenerative disorders. Domainex, a leading integrated medicines research services partner, will provide fully integrated lead optimization […]
NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson’s and Motor Neurone Disease
£2.68 million Biomedical Catalyst (BMC) early-stage award funded in part by Innovate UK to support development of disease-modifying medicines for debilitating chronic neurodegenerative disorders NRG has a pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson’s disease (PD) and motor neurone disease (MND) NRG […]
NRG Therapeutics Completes MND Therapeutic Analysis Project with Medicines Discovery Catapult Supported by an Innovate UK EDGE Grant
NRG’s second therapeutic programme to explore brain penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) as treatment for MND (ALS) Innovate UK EDGE grant enabled support from the Medicines Discovery Catapult Scientific and commercial insights gained will support MND clinical study design and Series A financing NRG Therapeutics Ltd (“NRG” or “company”), […]
NRG Therapeutics Launches MND Drug Discovery Programme and Announces new Collaboration in Australia
NRG’s second therapeutic programme to explore brain penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) as treatment for MND (ALS) Research collaboration agreement with Australia’s WEHI to work with Associate Professor Seth Masters’ group, on back of groundbreaking research 1 NRG is industrial partner in recent AUD$1 million FightMND Grant to WEHI […]